Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $6.1150 (1.24%) ($6.1150 - $6.1150) on Fri. Sep. 1, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.32% (three month average) | RSI | 33 | Latest Price | $6.1150(1.24%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | IOVA declines -5% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) IPO(42%) SLV(41%) GDX(39%) GDXJ(36%) BLOK(35%) | Factors Impacting IOVA price | IOVA will decline at least -2.16% in a week (0% probabilities). UUP(-44%) TAN(-41%) TBT(-31%) XRT(-23%) VXX(-17%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.16% (StdDev 4.32%) | Hourly BBV | -0.3 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-9.48(-255.03%) | Resistance Level | $6.55 | 5 Day Moving Average | $6.1(0.25%) | 10 Day Moving Average | $6.16(-0.73%) | 20 Day Moving Average | $6.55(-6.64%) | To recent high | -30.8% | To recent low | 1.2% | Market Cap | $895m | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |